Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Kalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPA
Professor
University of Florida College of Pharmacy

Joshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.
2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-312-H01-P
Initial release date: 11/3/2025
Expiration date: 11/3/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Jamie Pitlick, PharmD, BCPS, BC-ADM
Professor and Chair of Pharmacy Practice
Drake University College of Pharmacy and Health Sciences

Joshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders.
2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-311-H01-P
Initial release date: 10/27/2025
Expiration date: 10/27/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Zachary Cox, PharmD
Professor
Lipscomb University College of Pharmacy

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.
2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-299-H01-P
Initial release date: 10/20/2025
Expiration date: 10/20/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram